In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene

Haemophilia

Volumn 20, Issue 2, 2014, Pages 176-184

  Pashov, A D ^a,b   Calvez, T ^c   Gilardin, L ^a   Maillere B ^d   Repesse Y ^e   Oldenburg, J ^f   Pavlova, A ^f   Kaveri, S V ^a,g   Lacroix Desmazes, S ^a,g  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b BULGARIAN ACADEMY OF SCIENCES   (Bulgaria)

^c SORBONNE UNIVERSITÉ   (France)

^d SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^e CAEN UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL BONN   (Germany)

^g NATIONAL INSTITUTE OF IMMUNOHAEMATOLOGY   (India)

Author keywords

Factor VIII; Immunogenicity; MHC class II; Missense mutations; Prediction; T cell epitopes

Indexed keywords

FACTOR VIII; IMMUNOGENICITY; MHC CLASS II; MISSENSE MUTATIONS; PREDICTION; T-CELL EPITOPES;

AMINO ACID SEQUENCE; DATABASES, GENETIC; EPITOPES; FACTOR VIII; HEMOPHILIA A; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; ISOANTIBODIES; MUTATION, MISSENSE; PEPTIDE FRAGMENTS; PROTEIN BINDING; RISK FACTORS;

EID: 84894286004     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12276     Document Type: Article

References (48)

1. Mannucci PM, Tuddenham EG. The hemophilias-from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
2. Graw J, Brackmann HH, Oldenburg J, Schneppenheim R, Spannagl M, Schwaab R. Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet 2005; 6: 488-501.
3. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
4. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
5. Algiman M, Dietrich G, Nydegger U, Boieldieu D, Sultan Y, Kazatchkine MD. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci USA 1992; 89: 3795-9.
6. Moreau A, Lacroix-Desmazes S, Stieltjes N et al. Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity, are present in the plasma of non-responder patients with severe hemophilia A and healthy blood donors. Blood 2000; 95: 3435-41.
7. + T-cell epitope repertoire on the C2 domain of coagulation factor VIII. J Thromb Haemost 2003; 1: 1777-84.
8. Reding MT, Okita DK, Diethelm-Okita BM, Anderson TA, Conti-Fine BM. Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation factor VIII. J Thromb Haemost 2004; 2: 1385-94.
9. + T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects. Thromb Haemost 1999; 82: 509-15.
10. Rossi F, Dietrich G, Kazatchkine MD. Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev 1989; 110: 135-49.
11. Rossi F, Sultan Y, Kazatchkine MD. Anti-idiotypes against autoantibodies and alloantibodies to factor VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol 1988; 74: 311-6.
12. Kamate C, Lenting PJ, van den Berg HM, Mutis T. Depletion of CD4(+)CD25(high) regulatory T cells may enhance or uncover factor VIII-specific T cell responses in healthy individuals. J Thromb Haemost 2007; 5: 611-3.
13. Lacroix-Desmazes S, Navarrete AM, Andre S, Bayry J, Kaveri SV, Dasgupta S. Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood 2008; 112: 240-9.
14. Collins PW, Hirsch S, Baglin TP et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007; 109: 1870-7.
15. Gouw SC, van den Berg HM, Oldenburg J et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012; 119: 2922-34.
16. Schwaab R, Brackmann H-H, Meyer C et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
17. Viel KR, Ameri A, Abshire TC et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009; 360: 1618-27.
18. Schwarz J, Astermark J, Menius ED et al. F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Haemophilia 2013; 19: 113-8.
19. Oldenburg J, El-Maarri O. New insight into the molecular basis of hemophilia A. Int J Hematol 2006; 83: 96-102.
20. Astermark J, Oldenburg J, Carlson J et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739-45.
21. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72.
22. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263-5.
23. Pavlova A, Delev D, Lacroix-Desmazes S et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost 2009; 7: 2006-15.
24. Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77: 238-42.
25. Hay CR, Ollier W, Pepper L et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 1997; 77: 234-7.
26. Astermark J, Donfield SM, Gomperts ED et al. The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood 2013; 121: 1446-54.
27. Eckhardt CL, Menke LA, van Ommen CH et al. Intensive peri-operative use of factor VIII and the Arg593->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J Thromb Haemost 2009; 7: 930-7.
28. Bril WS, MacLean PE, Kaijen PH et al. HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg593 to Cys mutation. Haemophilia 2004; 10: 509-14.
29. Kemball-Cook G, Tuddenham EG, Wacey AI. The factor VIII structure and mutation resource site: HAMSTeRS version 4. Nucleic Acids Res 1998; 26: 216-9.
30. Vita R, Zarebski L, Greenbaum JA et al. The immune epitope database 2.0. Nucleic Acids Res 2010; 38: D854-62.
31. Nielsen M, Lund O. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics 2009; 10: 296.
32. Nielsen M, Lundegaard C, Blicher T et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS ONE 2007; 2: e796.
33. Bui HH, Sidney J, Peters B et al. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 2005; 57: 304-14.
34. Nielsen M, Lundegaard C, Blicher T et al. Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan. PLoS Comput Biol 2008; 4: e1000107.
35. Sturniolo T, Bono E, Ding J et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 1999; 17: 555-61.
36. Wang P, Sidney J, Dow C, Mothe B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 2008; 4: e1000048.
37. Lin HH, Zhang GL, Tongchusak S, Reinherz EL, Brusic V. Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinformatics 2008; 9(Suppl. 12): S22.
38. Delluc S, Ravot G, Maillere B. Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential. Blood 2010; 116: 4542-5.
39. Wang P, Sidney J, Kim Y et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics 2010; 11: 568.
40. Green PM, Bagnall RD, Waseem NH, Giannelli F. Haemophilia A mutations in the UK: results of screening one-third of the population. Br J Haematol 2008; 143: 115-28.
41. Yanover C, Jain N, Pierce G, Howard TE, Sauna ZE. Pharmacogenetics and the immunogenicity of protein therapeutics. Nat Biotechnol 2011; 29: 870-3.
42. Pashov AD, Kaveri SV, Lacroix-Desmazes S. Missense Mutations Disrupting Promiscuous Class II Self-Epitopes are Associated with Development of Inhibitory Antibodies to Factor VIII. Philadelphia, PA: Immunogenicity Summit, 2010.
43. van Haren SD, Herczenik E, ten Brinke A, Mertens K, Voorberg J, Meijer AB. HLA-DR-presented peptide repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIII. Mol Cell Proteomics 2011; 10: M110.002246. doi: 10.1016/j.blre.2011.10.001.
44. + T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice. Blood 2012; 119: 4073-82.
45. Astermark J, Donfield SM, Gomperts ED et al. The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood 2013; 121: 1446-54.
46. Dimitrov JD, Roumenina LT, Plantier JL et al. A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope. J Thromb Haemost 2010; 8: 1524-31.
47. Vlot AJ, Koppelman SJ, Meijers JCM et al. Kinetics of factor VIII-von Willebrand factor association. Blood 1996; 87: 1809-16.
48. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983-96.